Kartik Cherabuddi, MD, FACP, FIDSA
Professor Of Medicine, Antibiotic Stewardship Program Director
Department:
MD-INFECTIOUS DISEASES
Business Phone:
(352) 294-5481
Business Email:
kartikeya.cherabuddi@medicine.ufl.edu
About Kartik Cherabuddi
Dr. Kartik Cherabuddi provides clinical care to patients with complex infectious diseases; patients living with HIV; and internal medicine patients. He serves as a specialist for antibiotic resistant pathogen infections and is the Director of Antimicrobial Stewardship Program at UFHealth.
A Master Clinician Society at UF inductee, Dr. Cherabuddi is a recognized Exemplary Clinician for multiple years for excellence in teaching through the Department of Medicine. He enjoys teaching medical students, residents and ID fellows. He has been recognized as the DOM Attending of the year by the residents.
Dr. Cherabuddi conducts research looking at Antibiotic resistance and genetic sequencing of microorganisms. He also collaborates with researchers at the UF Emerging Pathogen Institute on (re)emerging viral infections including Zika, Chikungunya and Keystone viruses.
Dr. Cherabuddi also serves on international infectious diseases committees to develop enhanced training in Antibiotic Stewardship. He has advised and volunteered with education efforts around the world, including in Asia (India, Nepal) and Africa (Democratic Republic of Congo), in regards to COVID-19 control and management. He has participated in multiple interviews with national and international news media and continues education dispelling medical misinformation.
Additional Positions:
Director of Infectious Diseases
2020 – Current
·
Select Hospital, GNV
Pharmacy & Therapeutics Program Director
2020 – Current
·
Select Hospital, GNV
Hospital Epidemiologist, Associate
2015 – Current
·
UF Health
Antimicrobial Management Program Director
2014 – Current
·
UF Health
Related Links:
Teaching Profile
Courses Taught
2020
BMS6634 GI and Hepatology
2018
MDT7090 Elective Topics
2018
MDC7203 Senior Medicine Clerk
2018
MDC7124 Family Med/Geriatrics
2016,2018
MDC7200 Medicine Clerkship
2018,2024
BMS6300 Fund Micro and Immuno
2016-2018
MDT7200 Elect Top/Medicine
2021-2024
PAS5020 Intro to Medicine 2
2023-2024
BMS6810 Intro Clin Med 1
2023-2024
BMS6020 Clinical Neuroscience
2024
BMS6631 Hematology
Board Certifications
-
Infectious DiseasesAmerican Board of Multiple Specialties
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Infectious Disease
Areas of Interest
- Infectious endocarditis
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Osteomyelitis
- Secondary infections
- Surgical wound infection – treatment
- Transplant services
- Urinary tract infection – adults
Research Profile
Multidrug resistant infections
Antimicrobial alternatives to antibiotics
Therapeutic drug monitoring and personalized medicine
Emerging global infections
NTM infections in Transplant patients
Infectious disease fellow, Internal medicine resident and Medical student education
Open Researcher and Contributor ID (ORCID)
0000-0001-7390-9053
Publications
2024
Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV.
International journal of STD & AIDS.
[DOI] 10.1177/09564624241238813.
[PMID] 38502040.
2023
A new antifungal drug for candidaemia
The Lancet Infectious Diseases.
23(6)
[DOI] 10.1016/s1473-3099(23)00307-9.
2023
Analysis of Two-Step Clostridioides Difficile Testing on Case Reporting, Cycle Threshold Value and Treatment Choice
American Journal of Infection Control.
51(7)
[DOI] 10.1016/j.ajic.2023.04.015.
2023
Digital cough monitoring – A potential predictive acoustic biomarker of clinical outcomes in hospitalized COVID-19 patients.
Journal of biomedical informatics.
138
[DOI] 10.1016/j.jbi.2023.104283.
[PMID] 36632859.
2023
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021.
Open forum infectious diseases.
10(11)
[DOI] 10.1093/ofid/ofad511.
[PMID] 38023544.
2023
Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
JAC-Antimicrobial Resistance.
5(2)
[DOI] 10.1093/jacamr/dlad021.
[PMID] 36936190.
2023
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
JAMA.
329(14):1170-1182
[DOI] 10.1001/jama.2023.3546.
[PMID] 37039791.
2023
Seafood-Associated Outbreak of ctx-Negative Vibrio mimicus Causing Cholera-Like Illness, Florida, USA.
Emerging infectious diseases.
29(10):2141-2144
[DOI] 10.3201/eid2910.230486.
[PMID] 37735754.
2023
Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.
Pharmacotherapy.
43(1):6-14
[DOI] 10.1002/phar.2744.
[PMID] 36401796.
2022
952: BETA-LACTAM EXPOSURE IN ICU PATIENTS AND ASSOCIATED OUTCOMES: A PROSPECTIVE OBSERVATIONAL STUDY
Critical Care Medicine.
50(1):473-473
[DOI] 10.1097/01.ccm.0000810132.12952.d2.
2022
Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.
Antimicrobial agents and chemotherapy.
66(2)
[DOI] 10.1128/AAC.02046-21.
[PMID] 34902271.
2022
Development of a Prediction Model for Antibiotic-Resistant Urinary Tract Infections Using Integrated Electronic Health Records from Multiple Clinics in North-Central Florida.
Infectious diseases and therapy.
11(5):1869-1882
[DOI] 10.1007/s40121-022-00677-x.
[PMID] 35908268.
2022
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial.
JAMA network open.
5(3)
[DOI] 10.1001/jamanetworkopen.2022.2735.
[PMID] 35294537.
2022
Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
79(18):1586-1591
[DOI] 10.1093/ajhp/zxac171.
[PMID] 35704702.
2022
Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI).
Antimicrobial stewardship & healthcare epidemiology : ASHE.
2(1)
[DOI] 10.1017/ash.2022.21.
[PMID] 36310806.
2022
Resource Over-Utilization in Hospitalized Patients With Uncomplicated Skin and Soft Tissue Infections.
Journal of pharmacy practice.
35(5):675-679
[DOI] 10.1177/08971900211000216.
[PMID] 33752488.
2022
Use of Novel Strategies to Develop Guidelines for Management of Pyogenic Osteomyelitis in Adults: A WikiGuidelines Group Consensus Statement.
JAMA network open.
5(5)
[DOI] 10.1001/jamanetworkopen.2022.11321.
[PMID] 35536578.
2021
1101. Implementing a Beta-Lactam Therapeutic Drug Monitoring Program: Experience from a Large Academic Medical Center
Open Forum Infectious Diseases.
8(Supplement_1):S642-S642
[DOI] 10.1093/ofid/ofab466.1295.
2021
1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
Open Forum Infectious Diseases.
8(Supplement_1):S717-S718
[DOI] 10.1093/ofid/ofab466.1449.
2021
Dissemination mechanisms of NDM genes in hospitalized patients
JAC-Antimicrobial Resistance.
3(1)
[DOI] 10.1093/jacamr/dlab032.
[PMID] 34223104.
2021
Draft Genome Sequence of a Burkholderia cepacia Complex Strain Isolated from a Human Intra-abdominal Abscess.
Microbiology resource announcements.
10(11)
[DOI] 10.1128/MRA.00091-21.
[PMID] 33737360.
2021
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
New England Journal of Medicine.
385(21):1951-1960
[DOI] 10.1056/nejmoa2103784.
2021
In-Frame 12-Nucleotide Deletion within Open Reading Frame 3a in a SARS-CoV-2 Strain Isolated from a Patient Hospitalized with COVID-19.
Microbiology resource announcements.
10(8)
[DOI] 10.1128/MRA.00137-21.
[PMID] 33632859.
2021
India’s COVID-19 crisis: a call for international action.
Lancet (London, England).
397(10290):2132-2135
[DOI] 10.1016/S0140-6736(21)01121-1.
[PMID] 34000256.
2021
Investing in the Future: A Role for Professional Societies to Prepare the Next Generation of Healthcare Leaders Through Curriculum Development and Dissemination.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
73(5):911-918
[DOI] 10.1093/cid/ciab244.
[PMID] 33730751.
2021
Performance of a Semiquantitative Multiplex Bacterial and Viral PCR Panel Compared With Standard Microbiological Laboratory Results: 396 Patients Studied With the BioFire Pneumonia Panel
Open Forum Infectious Diseases.
8(1)
[DOI] 10.1093/ofid/ofaa560.
[PMID] 33447631.
2021
Relationship of Multiplex Molecular Pneumonia Panel Results With Hospital Outcomes and Clinical Variables.
Open forum infectious diseases.
8(8)
[DOI] 10.1093/ofid/ofab368.
[PMID] 34458392.
2021
Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar
Healthcare.
9(3)
[DOI] 10.3390/healthcare9030351.
[PMID] 33808758.
2020
1111. #BeASteward: Transforming Infectious Diseases Fellows Into Antimicrobial Stewards Using the IDSA Antimicrobial Stewardship Curriculum
Open Forum Infectious Diseases.
7(Supplement_1):S585-S586
[DOI] 10.1093/ofid/ofaa439.1297.
2020
1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
Open Forum Infectious Diseases.
7(Supplement_1):S786-S787
[DOI] 10.1093/ofid/ofaa439.1756.
2020
Chloroquine and hydroxychloroquine in the context of COVID-19.
Drugs in context.
9
[DOI] 10.7573/dic.2020-4-5.
[PMID] 32373183.
2020
Clostridioides difficile associated peritonitis in peritoneal dialysis patients – a case series based review of an under-recognized entity with therapeutic challenges.
BMC nephrology.
21(1)
[DOI] 10.1186/s12882-020-01734-8.
[PMID] 32131755.
2020
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients
Journal of Antimicrobial Chemotherapy.
75(12):3644-3651
[DOI] 10.1093/jac/dkaa359.
2020
Optimizing COVID-19 testing capabilities and clinical management using pathology informatics
JAMIA Open.
3(4):523-529
[DOI] 10.1093/jamiaopen/ooaa055.
2020
Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.
Antimicrobial agents and chemotherapy.
64(9)
[DOI] 10.1128/AAC.00745-20.
[PMID] 32601155.
2020
Severe COVID-19 After Recent Heart Transplantation Complicated by Allograft Dysfunction.
JACC. Case reports.
2(9):1347-1350
[DOI] 10.1016/j.jaccas.2020.05.066.
[PMID] 32835277.
2020
Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.08.03.20167395.
[PMID] 32793914.
2020
Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
100:476-482
[DOI] 10.1016/j.ijid.2020.09.025.
[PMID] 32949774.
2019
1548. Characterizing Cefepime Neurotoxicity: Experience from a Tertiary Care Center Performing β-lactam Therapeutic Drug Monitoring
Open Forum Infectious Diseases.
6(Supplement_2):S565-S565
[DOI] 10.1093/ofid/ofz360.1412.
2019
Application of an objective structured clinical examination to evaluate and monitor intern’s proficiency of hand hygiene and personal protective equipment use in the United States.
Journal of educational evaluation for health professions.
16
[DOI] 10.3352/jeehp.2019.16.31.
[PMID] 31614408.
2019
Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections.
Antimicrobial agents and chemotherapy.
63(11)
[DOI] 10.1128/AAC.00788-19.
[PMID] 31427300.
2019
Keystone Virus Isolated From a Florida Teenager With Rash and Subjective Fever: Another Endemic Arbovirus in the Southeastern United States?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
68(1):143-145
[DOI] 10.1093/cid/ciy485.
[PMID] 29893806.
2019
Prophylactic antibiotics in head and neck free flap surgery: A novel protocol put to the test.
American journal of otolaryngology.
40(6)
[DOI] 10.1016/j.amjoto.2019.102276.
[PMID] 31447185.
2018
1181. Use of the Combination Antibiogram in the Era of MDR Gram-Negative Pathogens
Open Forum Infectious Diseases.
5(suppl_1):S357-S357
[DOI] 10.1093/ofid/ofy210.1014.
2018
2425. Clinical and Microbiologic Outcomes Among Patients With Monomicrobial Stenotrophomonas maltophilia Infections
Open Forum Infectious Diseases.
5(suppl_1):S725-S725
[DOI] 10.1093/ofid/ofy210.2078.
2018
Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): a single-center university hospital experience.
International journal of antimicrobial agents.
51(1):57-61
[DOI] 10.1016/j.ijantimicag.2017.06.008.
[PMID] 28666756.
2018
Antifungal Potential of Host Defense Peptide Mimetics in a Mouse Model of Disseminated Candidiasis
Journal of Fungi.
4(1)
[DOI] 10.3390/jof4010030.
[PMID] 29495524.
2018
Antimicrobial Stewardship Training for Infectious Diseases Fellows: Program Directors Identify a Curriculum Need.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
67(8):1285-1287
[DOI] 10.1093/cid/ciy332.
[PMID] 29668905.
2018
Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms
International Journal of Antimicrobial Agents.
52(5):719-723
[DOI] 10.1016/j.ijantimicag.2018.08.007.
2018
Peripheral T-cell lymphoma mimicking classic Hodgkin’s lymphoma in a patient presenting with fevers of unknown origin.
BMJ case reports.
2018
[DOI] 10.1136/bcr-2017-220858.
[PMID] 29420242.
2018
Pertuzumab and trastuzumab infusion related cytokine release syndrome in a chemotherapy naive patient with metastatic breast cancer.
The breast journal.
24(3):383-384
[DOI] 10.1111/tbj.12943.
[PMID] 29027290.
2018
SCAN: A novel approach for vancomycin time-out.
Infection control and hospital epidemiology.
39(12):1501-1503
[DOI] 10.1017/ice.2018.249.
[PMID] 30303049.
2017
Coinfection With Zika and Dengue-2 Viruses in a Traveler Returning From Haiti, 2016: Clinical Presentation and Genetic Analysis
Clinical Infectious Diseases.
64(1):72-75
[DOI] 10.1093/cid/ciw667.
[PMID] 27694479.
2017
Impact of an Extended Infusion Β-lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections
Open Forum Infectious Diseases.
4(suppl_1):S299-S299
[DOI] 10.1093/ofid/ofx163.689.
2017
Potent in vitro and in vivo antifungal activity of a small molecule host defense peptide mimic through a membrane-active mechanism.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-04462-6.
[PMID] 28659617.
2017
Reduced Mortality with Early Infectious Disease Consultation in Patients with AmpC Gram-negative Bacteremia
Open Forum Infectious Diseases.
4(suppl_1):S555-S555
[DOI] 10.1093/ofid/ofx163.1444.
2017
Refractory acute respiratory failure due to Pneumocystis jiroveci (PCP) and Cytomegalovirus (CMV) pneumonitis: A case report and review of literature.
IDCases.
10:42-45
[DOI] 10.1016/j.idcr.2017.08.011.
[PMID] 28879093.
2017
Successful Treatment of Clostridium difficile Bacteremia with Aortic Mycotic Aneurysm in a Patient with Prior Endovascular Aortic Aneurysm Repair.
Case reports in infectious diseases.
2017
[DOI] 10.1155/2017/8472930.
[PMID] 28348903.
2016
A decade of antimicrobial stewardship at the University of Florida – Challenges, strategies and outcomes
International Journal of Infectious Diseases.
45:44-45
[DOI] 10.1016/j.ijid.2016.02.141.
2016
Case of eastern equine encephalitis presenting in winter.
BMJ case reports.
2016
[DOI] 10.1136/bcr-2016-215270.
[PMID] 27165999.
2016
Clinical Utility of Cefepime for the Management of Bacteremia Secondary to AmpC-Producing Organisms
Open Forum Infectious Diseases.
3(suppl_1)
[DOI] 10.1093/ofid/ofw172.758.
2016
Zika and Chikungunya virus co-infection in a traveller returning from Colombia, 2016: virus isolation and genetic analysis.
JMM case reports.
3(6)
[DOI] 10.1099/jmmcr.0.005072.
[PMID] 28348794.
2014
Applying athletic principles to medical rounds to improve teaching and patient care.
Academic medicine : journal of the Association of American Medical Colleges.
89(7):1018-23
[DOI] 10.1097/ACM.0000000000000278.
[PMID] 24979169.
2012
Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: a multihospital study.
Infection control and hospital epidemiology.
33(12):1193-9
[DOI] 10.1086/668435.
[PMID] 23143355.
Grants
Oct 2022
ACTIVE
UF and FDOH Collaboration for "Nursing Home and Long Term Care Facility Strike Team and Infrastructure Project"
Role: Other
Funding: FL DEPT OF HLTH
via CTRS FOR DISEASE CONTROL AND PREVENTION
Nov 2021
– Apr 2023
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard of Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Righ
Role: Principal Investigator
Funding: CONTRAFECT CORPORATION
via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Apr 2021
– Mar 2022
CoVPN 3006 Protocol Funding (PF) – Gainesville Protocol-Specific Site
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
Apr 2021
ACTIVE
Dalbavancin as an Option for Treatment of S. aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Com
Role: Principal Investigator
Funding: DUKE UNIVERSITY
via NATL INST OF HLTH NIAID
Apr 2021
– Mar 2022
A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
Role: Principal Investigator
Funding: FORTREA
via NATL INST OF HLTH NHLBI
Mar 2021
– Mar 2024
ACTIV 4d RAAS
Role: Project Manager
Funding: VANDERBILT UNIVERSITY MEDICAL CENTER
via NATL INST OF HLTH NHLBI
Feb 2021
– Nov 2021
A randomized study to assess the efficacy of SARS-CoV-2 EUA vaccine in preventing SARS-CoV-2 infection and viral shedding in US college students
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
Oct 2020
– Jul 2023
Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study
to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Jul 2020
ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Oct 2018
– Dec 2020
CRBSI/CLABSI Infection Detection Project
Role: Principal Investigator
Funding: ARROW INTERNATIONAL
Feb 2018
– Nov 2019
A Phase 2 Proof-of-Concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa
Role: Principal Investigator
Funding: DUKE UNIVERSITY MEDICAL CTR
via NATL INST OF HLTH NIAID
Jan 2011
– Jan 2019
A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects
Role: Principal Investigator
Funding: DUKE UNIVERSITY MEDICAL CTR
via NATL INST OF HLTH NIAID
Education
Fellowship – Infectious Diseases and Global Medicine
2011-2013
·
University of Florida
Chief Resident – Internal Medicine
2010-2011
·
Westlake – Loyola University
Residency – Internal Medicine
2007-2010
·
Westlake – Loyola University
Rotating Internship
2004-2005
·
Kakatiya Medical College
Bachelor of Medicine, Bachelor of Surgery
1998-2003
·
Kakatiya Medical College
Contact Details
Phones:
- Business:
- (352) 294-5481
Emails:
- Business:
- kartikeya.cherabuddi@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100289
GAINESVILLE FL 32610